In the current immunotherapy era, programmed death ligand-1 (PD-L1) expression, tumor mutational burden (TMB), microsatellite instability (MSI), HPV status, smoking status, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), gut or oral cavity microbiota, and tumor-microenvironment-related gene expression profiles have been suggested as potential immune biomarkers to predict the efficacy of immune checkpoint inhibitors [12]. This evidence concerns the gene CD274 and neoplasm.